Stephen Bloch, EvolveImmune CEO
AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65M
AbbVie, already a leader in the T cell engager field with Epkinly and a Phase 3 program, is further digging into the field with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
